Market Overview:
The global glucagon like peptide-1 (GLP-1) agonists market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about GLP-1 receptor agonists, and technological advancements in the field of drug delivery. Based on type, the global GLP-1 receptor agonist market is segmented into exenatide, liraglutide, lixisenatide, albiglutide, and dulaglutide. Liraglutide held the largest share of this market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy and safety profile as well as its wide patient base. Based on application, hospital held the largest share of this market in 2017 and is expected to maintain its dominance during the forecast period.
 Agonists Industry Outlook.svg)
Product Definition:
A glucagon-like peptide-1 (GLP-1) agonist is a drug that stimulates the body to release insulin in response to high blood sugar levels, as well as slow the emptying of the stomach after eating. GLP-1 agonists are used to treat type 2 diabetes.
Exenatied:
Exenatied is a peptide hormone that reduces the release of insulin after meals. It was first identified in 1999 and has been studied extensively since then. Exenatied Peptide (ExP) has an amino acid sequence similar to human GLP-1, thus the name by which it is known as well.
Liraglutide:
Liraglutide is a GLP-1 receptor agonist developed by Novartis AG. It was approved by the FDA in 2009 under the brand name Ofev for treatment of adult patients with type 2 diabetes who are unable to produce insulin.
Application Insights:
The other application segment includes the food and beverage industry. The growing demand for low-calorie products with a similar action to that of insulin is expected to drive this application segment over the forecast period. GLP-1 agonists are used in numerous diabetic snacks, such as cheese puffs, gourmet chips, cookies and cakes, fruit pies, chocolate bars and candies among others.
The increasing prevalence of diabetes has led to an increased demand for dietary supplements among other health care professionals who treat type 2 diabetes patients. This trend is expected to continue over the forecast period due largely in part to consumer awareness programs conducted by various manufacturers including Novo Nordisk A/S., Takeda Pharmaceutical Co., Ltd., Otsuka America Inc., Pfizer Canada Inc., Eli Lilly & Co.; JBS USA; DSM NV onlus; etc. These companies have launched innovative products such as incretin therapy drugs along with new drug applications (NDPs) before the U.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable government initiatives and increasing prevalence of diabetes. For instance, in November 2016, the U.S. FDA approved Onglyza (omalizumab) for commercial use following its approval as an orphan drug by the FDA in 2015 for treatment of adult-onset diabetes (type 1). In addition, a high number of product launches is also expected to drive growth during the forecast period.
Growth Factors:
- Increasing prevalence of type 2 diabetes mellitus (T2DM) is the major growth driver for GLP-1 agonists market. According to World Health Organization (WHO), the number of people with diabetes has quadrupled since 1980 and more than 422 million people are living with diabetes worldwide in 2014. This number is expected to increase to 642 million by 2040.
- Rising geriatric population is another key growth driver for GLP-1 agonists market as this population is more susceptible to develop T2DM and other chronic diseases associated with aging process such as obesity, hypertension, dyslipidemia, etc. For instance, according to United Nations Department of Economic and Social Affairs Population Division (UNDESA), global geriatric population was 729 million in 2015 and it is projected that this number will reach 1.6 billion by 2050 accounting for nearly 21% of world’s population.
- Technological advancements in drug delivery systems are also propelling the growth of GLP-1 agonists market as these systems help improve patient compliance rates owing to their ease-of-use features such as once or twice daily dosing regimens without any food restrictions compared with injectable formulations currently available in the market place . For instance, Insulet Corporation’s OmniPod® Insulin Management System offers a discreet, easy-to use tubeless insulin pump which delivers insulin under the skin through a small cannula using adhesive patches placed
Scope Of The Report
Report Attributes
Report Details
Report Title
Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report
By Type
Exenatied, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide
By Application
Hospital, Pharmacy, Other
By Companies
Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi, Bristol-Myers Squibb, Amylin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Report Segments:
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented on the basis of:
Types
Exenatied, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- AstraZeneca
- Eli Lilly
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
 Agonists Market Overview.svg)
Highlights of The Glucagon Like Peptide-1 (GLP-1) Agonists Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glucagon Like Peptide-1 (GLP-1) Agonists Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Agonists Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
GLP-1 agonists are peptides that mimic the actions of GLP-1. They help to reduce hunger and cravings, and can improve blood sugar control in people with diabetes.
Some of the key players operating in the glucagon like peptide-1 (glp-1) agonists market are Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi, Bristol-Myers Squibb, Amylin.
The glucagon like peptide-1 (glp-1) agonists market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glucagon Like Peptide-1 (GLP-1) Agonists Market - Supply Chain
4.5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast
4.5.1. Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Absolute $ Opportunity
5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Type
5.3.1. Exenatied
5.3.2. Liraglutide
5.3.3. Lixisenatide
5.3.4. Albiglutide
5.3.5. Dulaglutide
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Pharmacy
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Demand Share Forecast, 2019-2026
9. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Pharmacy
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Type
9.7.1. Exenatied
9.7.2. Liraglutide
9.7.3. Lixisenatide
9.7.4. Albiglutide
9.7.5. Dulaglutide
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glucagon Like Peptide-1 (GLP-1) Agonists Demand Share Forecast, 2019-2026
10. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Pharmacy
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Type
10.7.1. Exenatied
10.7.2. Liraglutide
10.7.3. Lixisenatide
10.7.4. Albiglutide
10.7.5. Dulaglutide
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Demand Share Forecast, 2019-2026
11. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Pharmacy
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Type
11.7.1. Exenatied
11.7.2. Liraglutide
11.7.3. Lixisenatide
11.7.4. Albiglutide
11.7.5. Dulaglutide
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Demand Share, 2019-2026
12. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Pharmacy
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Type
12.7.1. Exenatied
12.7.2. Liraglutide
12.7.3. Lixisenatide
12.7.4. Albiglutide
12.7.5. Dulaglutide
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Demand Share, 2019-2026
13. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Pharmacy
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Volume Forecast by Type
13.7.1. Exenatied
13.7.2. Liraglutide
13.7.3. Lixisenatide
13.7.4. Albiglutide
13.7.5. Dulaglutide
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Market Share Analysis
14.2. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors and Customers
14.3. Glucagon Like Peptide-1 (GLP-1) Agonists Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GSK
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol-Myers Squibb
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Amylin
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
